drugset / Trial / NCT07789600

Trial Evaluating the Analgesic Efficacy of Magnesium Sulfate as an Adjuvant to Bupivacaine in Local Wound Infiltration for Patients Undergoing Modified Radical Mastectomy (MRM) With Axillary Clearance

NCT07789600 ↗

Not yet recruiting 70 enrolled King Hussein Cancer Center
RandomizedParallel-groupTriple-blindSupportive care

Summary

This is a double-blind, randomized, controlled clinical trial evaluating the analgesic efficacy and safety of magnesium sulfate as an adjuvant to bupivacaine for local wound infiltration in patients undergoing modified radical mastectomy with axillary clearance. Participants will be randomized to receive either magnesium sulfate 750 mg with bupivacaine or the control intervention. Postoperative pain, analgesic requirements, and safety outcomes will be assessed during the postoperative period, including a follow-up safety assessment between Day 7 and Day 14 after surgery.

Timeline

Start
2026-09-01
Primary completion
2027-12-01
Completion
2028-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 750 mg Other
Comparator Bupivacaine Other / unclassified 100 mg Other

Indications

No indication recorded.